# HD0801 (NCT00784537)

> High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients

No report yet. It can be ordered.

- Indication: advanced stage Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00784537
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Fondazione Italiana Linfomi - ETS
- Conditions: Hodgkin's Lymphoma
- Interventions: ABVD; ABVD and Radiotherapy
- Enrollment: 520
- Primary outcome: To evaluate if patients resistant to the initial treatment for residual PET-positive masses after the first two courses of ABVD (PET-2 positive), can be salvaged by early shift to high-dose chemotherapy supported by stem cell rescue.

## Indexed commentary on HD0801 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=hd0801-nct00784537